LI
ADMA icon

Leap Investments’s ADMA Biologics ADMA Stock Holding History

Leap Investments’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		$302K Buy
+103,000
New +$296K 0.2% 206

Other funds holding ADMA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Leap Investments's ADMA Position: Q2 2020 in Review

Leap Investments opened a new position in ADMA Biologics (ADMA) in Q2 2020: 103,000 shares worth $302K. The stake represents 0.2% of the portfolio and ranks #206 among its holdings.

95 funds tracked by Wall St. Rank hold ADMA as of Q2 2020.

  • Leap Investments held 103,000 shares of ADMA Biologics worth $302K as of Q2 2020.
  • ADMA Biologics was a new Leap Investments position in Q2 2020.
  • ADMA Biologics made up 0.2% of Leap Investments's portfolio in Q2 2020, its #206 holding.
  • 95 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2020.

Based on Leap Investments's 13F filing for Q2 2020, filed 3 Aug 2020.